Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 184

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 184
---
 if we commercially sell any product that we may develop. For example,
we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing,
marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure
to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under
state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidate. Regardless of the merits or eventual outcome, liability
claims may result in:

    ●
    decreased demand for our product candidate or products that we may develop;

    ●
    injury to our reputation and significant negative media attention;

    ●
    withdrawal of clinical trial participants;

    ●
    significant costs to defend resulting litigation;

    ●
    substantial monetary awards to trial participants or patients;

    ●
    loss of revenue;

    ●
    reduced resources of our management to pursue our business strategy; and

    ●
    the inability to commercialize any products that we may develop.

Although we plan to maintain
general liability insurance, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability
litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, insurance coverage is becoming increasingly
expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against
potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidate,
which could adversely affect our business, financial condition, results of operations and prospects.

42

We will need to increase the size and capabilities
of our organization, and we may experience difficulties in managing this growth.

To execute our business plan,
we will need to rapidly add other management, accounting, regulatory, manufacturing and scientific staff. We currently have 13 full-time
employees in the United States, 9 full-time employees in the United Kingdom and retain the services of additional personnel on an independent
contractor basis. We will need to attract, retain and motivate a significant number of new additional managerial, operational, sales,
marketing, financial, and other personnel, as well as highly skilled scientific and medical personnel, and to expand our capabilities
to successfully pursue our research, development, manufacturing and commercialization efforts and secure